{"id":"NCT01237587","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Duloxetine in Adolescents With Juvenile Primary Fibromyalgia Syndrome","officialTitle":"Effect of Duloxetine 30/60 mg Once Daily Versus Placebo in Adolescents With Juvenile Primary Fibromyalgia Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03","primaryCompletion":"2017-05-31","completion":"2017-11-28","firstPosted":"2010-11-09","resultsPosted":"2018-08-14","lastUpdate":"2019-09-20"},"enrollment":184,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Fibromyalgia"],"interventions":[{"type":"DRUG","name":"Duloxetine","otherNames":["LY248686"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Duloxetine","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether duloxetine is safe and effective in the treatment of adolescents with Juvenile Primary Fibromyalgia Syndrome (JPFS).\n\nThis trial consists of two distinct study periods. A blinded treatment period of 13 weeks and an open label extension period of 26 weeks.","primaryOutcome":{"measure":"Change From Baseline to 13 Week Endpoint in Brief Pain Inventory (BPI) Modified Short Form-adolescent Version 24 Hour Average Pain Severity Item","timeFrame":"Baseline, 13 weeks","effectByArm":[{"arm":"Duloxetine - Acute","deltaMin":-1.62,"sd":0.247},{"arm":"Placebo - Acute","deltaMin":-0.97,"sd":0.244}],"pValues":[{"comp":"OG000 vs OG001","p":"0.052"}]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":24},"locations":{"siteCount":33,"countries":["United States","Argentina","India","Puerto Rico"]},"refs":{"pmids":["31138224"],"seeAlso":["http://www.lillytrialguide.com/en-US/studies/fibromyalgia/HMGW#?postal="]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":91},"commonTop":["Nausea","Headache","Vomiting","Decreased appetite","Dizziness"]}}